AbbVie As Patent Enemy: Suit vs. MedImmune Aims To Halt Humira Royalty
This article was originally published in The Pink Sheet Daily
Latest legal battle over Humira centers around validity of patent covered in 1995 license agreement between predecessor firms.
You may also be interested in...
Brand vs. Brand Patent Battles Heat Up, Focus On Big Drug Classes
Patent brawl between Merck and Gilead involving Sovaldi and Harvoni was one of the marquee litigation events of 2016; a compilation of disputes between brand-name companies over the past six years shows how consequential they can be.
Device Component Of Intarcia’s Diabetes Treatment ITCA 650 Worries FDA
If FDA chief scientist grants Intarcia’s request for advisory committee meeting, CDER wants to provide input on issues to be considered. Director Cavazzoni says the novel drug-device combination product does not notify the user of a critical failure or infusion status.
Paxlovid Gets FDA Panel Backing For Full Approval; Combating Rebound Misperception Urged
Patient advocate is sole committee member to vote against Paxlovid favorable benefit-risk profile, saying doctors do not know how to use the treatment. Members suggest conducting natural history studies on COVID rebound and publishing data that shows no clear association with Paxlovid.